Oral medroxyprogesterone in the treatment of metastatic breast cancer.

Abstract

In 47 postmenopausal women with evaluable breast cancer, oral medroxyprogesterone acetate (MPA) was given at a daily dose level of 400 mg. Patients with negative estrogen receptors, poor performance status, or nonresponse to previous endocrine therapy were excluded from this study. There were 25 (53%) responders to this agent. Periods of remission ranged from 5-26 months with a median of 10 and a mean of 12+ months. Higher rates of response were noted in women over 50 years of age, in patients with osseous metastasis, and in patients with a longer disease-free interval. Adverse effects included weight gain, Cushingoid appearance, skin rash, and vaginal discharge. In this selected group of patients, oral medroxyprogesterone at a dose level of 400 mg/day appeared to provide a significant frequency of tumor response.

• Authors: T Nemoto, J Patel, D Rosner, T L Dao
• Journal: Journal of surgical oncology (J Surg Oncol) Vol. 32 Issue 4 Pg. 211-3 (Aug 1986) ISSN: 0022-4790 [Print] United States
• PMID: 3736062 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Receptors, Estrogen
• Medroxyprogesterone

Topics

• Adult
• Age Factors
• Aged
• Body Weight (drug effects)
• Breast Neoplasms (analysis, drug therapy, pathology)
• Female
• Humans
• Medroxyprogesterone (adverse effects, therapeutic use)
• Middle Aged
• Neoplasm Metastasis
• Receptors, Estrogen (analysis)